Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Progenity stock | $2.96

Learn how to easily invest in Progenity stock.

Progenity Inc is a biotechnology business based in the US. Progenity shares (PROG) are listed on the NASDAQ and all prices are listed in US Dollars. Progenity employs 511 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Progenity

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PROG – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Progenity stock price (NASDAQ: PROG)

Use our graph to track the performance of PROG stocks over time.

Progenity shares at a glance

Information last updated 2021-10-24.
Latest market close$2.96
52-week range$0.72 - $8.20
50-day moving average $1.52
200-day moving average $2.30
Wall St. target price$6.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.28

Buy Progenity shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Progenity stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Progenity price performance over time

Historical closes compared with the close of $2.96 from 2021-10-22

1 week (2021-10-19) -1.33%
1 month (2021-09-24) 228.89%
3 months (2021-07-26) 15.63%
6 months (2021-04-26) -5.73%
1 year (2020-10-23) -62.58%
2 years (2019-10-22) N/A
3 years (2018-10-22) N/A
5 years (2016-10-22) N/A

Progenity financials

Revenue TTM $74.9 million
Gross profit TTM $-19,120,000
Return on assets TTM -86.16%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation $392.9 million

TTM: trailing 12 months

Shorting Progenity shares

There are currently 10.7 million Progenity shares held short by investors – that's known as Progenity's "short interest". This figure is 21.5% up from 8.8 million last month.

There are a few different ways that this level of interest in shorting Progenity shares can be evaluated.

Progenity's "short interest ratio" (SIR)

Progenity's "short interest ratio" (SIR) is the quantity of Progenity shares currently shorted divided by the average quantity of Progenity shares traded daily (recently around 18.2 million). Progenity's SIR currently stands at 0.59. In other words for every 100,000 Progenity shares traded daily on the market, roughly 590 shares are currently held short.

However Progenity's short interest can also be evaluated against the total number of Progenity shares, or, against the total number of tradable Progenity shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Progenity's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Progenity shares in existence, roughly 90 shares are currently held short) or 0.1306% of the tradable shares (for every 100,000 tradable Progenity shares, roughly 131 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Progenity.

Find out more about how you can short Progenity stock.

Progenity share dividends

We're not expecting Progenity to pay a dividend over the next 12 months.

Progenity overview

Progenity, Inc. , a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory.

Frequently asked questions

What percentage of Progenity is owned by insiders or institutions?
Currently 10.629% of Progenity shares are held by insiders and 65.265% by institutions.
How many people work for Progenity?
Latest data suggests 511 work at Progenity.
When does the fiscal year end for Progenity?
Progenity's fiscal year ends in December.
Where is Progenity based?
Progenity's address is: 4330 La Jolla Village Drive, San Diego, CA, United States, 92122
What is Progenity's ISIN number?
Progenity's international securities identification number is: US74319F1075

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site